| Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F (ab′) 2—a phase I study H Andersson, E Cederkrantz, T Bäck, C Divgi, J Elgqvist, J Himmelman, ... Journal of Nuclear Medicine 50 (7), 1153-1160, 2009 | 333 | 2009 |
| Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields S Lindegren, T Bäck, HJ Jensen Applied Radiation and Isotopes 55 (2), 157-160, 2001 | 176 | 2001 |
| The α-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of α-particles T Bäck, L Jacobsson Journal of Nuclear Medicine 51 (10), 1616-1623, 2010 | 139 | 2010 |
| Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal antibody MX35 J Elgqvist, H Andersson, T Bäck, R Hultborn, H Jensen, B Karlsson, ... Journal of Nuclear Medicine 46 (11), 1907-1915, 2005 | 102 | 2005 |
| α-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose J Elgqvist, H Andersson, T Bäck, I Claesson, R Hultborn, H Jensen, ... Journal of Nuclear Medicine 47 (8), 1342-1350, 2006 | 94 | 2006 |
| Therapeutic efficacy of astatine-211–labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice S Palm, T Bäck, I Claesson, A Danielsson, J Elgqvist, S Frost, R Hultborn, ... International Journal of Radiation Oncology* Biology* Physics 69 (2), 572-579, 2007 | 88 | 2007 |
| Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation … SI Park, J Shenoi, JM Pagel, DK Hamlin, DS Wilbur, N Orgun, AL Kenoyer, ... Blood, The Journal of the American Society of Hematology 116 (20), 4231-4239, 2010 | 85 | 2010 |
| Direct procedure for the production of 211At-labeled antibodies with an ε-lysyl-3-(trimethylstannyl) benzamide immunoconjugate S Lindegren, S Frost, T Bäck, E Haglund, J Elgqvist, H Jensen Journal of Nuclear Medicine 49 (9), 1537-1545, 2008 | 82 | 2008 |
| Comparison of the therapeutic efficacy of 211At-and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. H Andersson, S Palm, S Lindegren, T Bäck, L Jacobsson, G Leser, ... Anticancer research 21 (1A), 409-412, 2001 | 82 | 2001 |
| Realizing clinical trials with astatine-211: the chemistry infrastructure S Lindegren, P Albertsson, T Bäck, H Jensen, S Palm, E Aneheim Cancer Biotherapy & Radiopharmaceuticals 35 (6), 425-436, 2020 | 79 | 2020 |
| Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model JJ Orozco, T Bäck, A Kenoyer, ER Balkin, DK Hamlin, DS Wilbur, ... Blood, The Journal of the American Society of Hematology 121 (18), 3759-3767, 2013 | 70 | 2013 |
| 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an α-emitter in vivo T Bäck, H Andersson, CR Divgi, R Hultborn, H Jensen, S Lindegren, ... Journal of Nuclear Medicine 46 (12), 2061-2067, 2005 | 67 | 2005 |
| Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model DJ Green, M Shadman, JC Jones, SL Frayo, AL Kenoyer, MD Hylarides, ... Blood, The Journal of the American Society of Hematology 125 (13), 2111-2119, 2015 | 66 | 2015 |
| Intraperitoneal α-Emitting radioimmunotherapy with 211AT in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations A Hallqvist, K Bergmark, T Bäck, H Andersson, P Dahm-Kähler, ... Journal of Nuclear Medicine 60 (8), 1073-1079, 2019 | 64 | 2019 |
| Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior Y Dekempeneer, T Bäck, E Aneheim, H Jensen, J Puttemans, C Xavier, ... Molecular Pharmaceutics 16 (8), 3524-3533, 2019 | 60 | 2019 |
| Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model JM Pagel, AL Kenoyer, T Bäck, DK Hamlin, DS Wilbur, DR Fisher, SI Park, ... Blood, The Journal of the American Society of Hematology 118 (3), 703-711, 2011 | 59 | 2011 |
| Absorbed doses and risk estimates of 211At-MX35 F (ab') 2 in intraperitoneal therapy of ovarian cancer patients E Cederkrantz, H Andersson, P Bernhardt, T Bäck, R Hultborn, ... International Journal of Radiation Oncology* Biology* Physics 93 (3), 569-576, 2015 | 56 | 2015 |
| Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F (ab′) 2: therapeutic efficacy and myelotoxicity J Elgqvist, H Andersson, T Bäck, I Claesson, R Hultborn, H Jensen, ... Nuclear medicine and biology 33 (8), 1065-1072, 2006 | 51 | 2006 |
| The Curative and Palliative Potential of the Monoclonal Antibody MOv18 Labelled with 211At in Nude Mice with Intraperitoneally growing Ovarian Cancer … H Andersson, Sture Lindegren, Tom Bäck, Lars Jacobsson, Gunilla Leser ... Acta Oncologica 39 (6), 741-745, 2000 | 50 | 2000 |
| Comparison of therapeutic efficacy and biodistribution of 213Bi-and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model AME Gustafsson, T Bäck, J Elgqvist, L Jacobsson, R Hultborn, ... Nuclear medicine and biology 39 (1), 15-22, 2012 | 48 | 2012 |
Brian MillerUniversity of Colorado - Denver; University of ArizonaAdresse e-mail validée de optics.arizona.edu